Sunshine Biopharma Inc. (SBFM): Entry into a Material Definitive Agreement
Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 sunshine_ex1001.htm AT-THE-MARKET ISSUANCE SALES AGREEMENT, Exhibit 10.1 AT-THE-MARKET ISSUANCE SALES AGREEMENT July 20, 2026 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sunshine Biopharma Inc., a Colorado corpora
How this was made
The 30-second read
Why it matters
The ATM structure enables the company to sell common stock from time to time through a sales agent, subject to a maximum aggregate amount, creating potential dilution and financing flexibility.
Market read
Traders may reassess dilution risk and financing runway based on the new ATM cap and the likelihood of near-term share sales.
What to watch
The excerpt does not state whether any shares were sold yet, the commission/discount terms, or the company’s cash needs, which can materially change the real dilution risk.
Background
The 8-K discloses entry into a material definitive agreement for an at-the-market issuance sales agreement tied to an existing Form S-3 shelf registration.
Ticker impact
Sunshine Biopharma entered an at-the-market equity sales agreement with Aegis Capital, capped at $4.0 million or shelf capacity.
Likely near-term pressure or higher volatility as traders price potential dilution, especially if the company draws on the ATM.
An 8-K Item 1.01 plus the ATM agreement is a primary-source capital-raise structure. The excerpt includes the maximum aggregate issuance limit, but not expected timing or actual draw size, so magnitude is uncertain.
Market effects
Adds to the broader small-cap biotech financing backdrop where ATM programs can be used to fund operations.
Primarily impacts US small-cap sentiment and liquidity.
Limited direct global spillover; mostly company-specific dilution risk.
Counterpoint
If the company uses the ATM opportunistically at higher prices, dilution could be minimized and the overhang may fade quickly.
Key entities
- issuerSunshine Biopharma Inc.
Subject of the 8-K and party entering the at-the-market equity sales agreement.
- sales_agentAegis Capital Corp.
Exclusive sales agent under the ATM agreement for selling placement shares.
